RARE vs. IOVA
Compare and contrast key facts about Ultragenyx Pharmaceutical Inc. (RARE) and Iovance Biotherapeutics, Inc. (IOVA).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: RARE or IOVA.
Key characteristics
| RARE | IOVA | |
|---|---|---|
| YTD Return | 6.78% | 40.71% |
| 1Y Return | 31.50% | 171.73% |
| 3Y Return (Ann) | -15.14% | -23.05% |
| 5Y Return (Ann) | 6.38% | -11.68% |
| 10Y Return (Ann) | 1.34% | 5.37% |
| Sharpe Ratio | 0.92 | 2.12 |
| Sortino Ratio | 1.57 | 3.03 |
| Omega Ratio | 1.19 | 1.35 |
| Calmar Ratio | 0.49 | 2.00 |
| Martin Ratio | 2.94 | 5.67 |
| Ulcer Index | 13.44% | 34.38% |
| Daily Std Dev | 42.56% | 91.75% |
| Max Drawdown | -82.11% | -99.37% |
| Current Drawdown | -71.22% | -92.81% |
Fundamentals
| RARE | IOVA | |
|---|---|---|
| Market Cap | $4.71B | $3.40B |
| EPS | -$7.22 | -$1.67 |
| PEG Ratio | -0.24 | 0.00 |
| Total Revenue (TTM) | $383.25M | $32.30M |
| Gross Profit (TTM) | $314.68M | -$31.06M |
| EBITDA (TTM) | -$367.24M | -$310.41M |
Correlation
The correlation between RARE and IOVA is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
RARE vs. IOVA - Performance Comparison
In the year-to-date period, RARE achieves a 6.78% return, which is significantly lower than IOVA's 40.71% return. Over the past 10 years, RARE has underperformed IOVA with an annualized return of 1.34%, while IOVA has yielded a comparatively higher 5.37% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
RARE vs. IOVA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and Iovance Biotherapeutics, Inc. (IOVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
RARE vs. IOVA - Dividend Comparison
Neither RARE nor IOVA has paid dividends to shareholders.
Drawdowns
RARE vs. IOVA - Drawdown Comparison
The maximum RARE drawdown since its inception was -82.11%, smaller than the maximum IOVA drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for RARE and IOVA. For additional features, visit the drawdowns tool.
Volatility
RARE vs. IOVA - Volatility Comparison
The current volatility for Ultragenyx Pharmaceutical Inc. (RARE) is 7.08%, while Iovance Biotherapeutics, Inc. (IOVA) has a volatility of 17.22%. This indicates that RARE experiences smaller price fluctuations and is considered to be less risky than IOVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
RARE vs. IOVA - Financials Comparison
This section allows you to compare key financial metrics between Ultragenyx Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities